Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Non-Hodgkin Lymphoma Clinical Trial

Official title:

Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05389423
• Other study ID #: 10000274
• Secondary ID: 000274-C
• Status: Recruiting
• Phase: Phase 1
• Start date: June 27, 2023
• Est. completion date: June 1, 2032

Study information

• Verified date: June 4, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Anaida Widell
• Phone: (240) 760-6074
• Email: anaida.widell[@]nih.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background:

Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more likely to get NHL than people who do not have HIV. The disease may also be different in these two groups. More study is needed for treating

people with both HIV and NHL.

Objective:

To test a study drug (pomalidomide) in combination with chemotherapy with or without another drug (rituximab) in people with HIV-associated NHL.

Eligibility:

Adults aged 18 years or older diagnosed with HIV-associated B-cell NHL with high-risk features.

Design:

Participants will undergo screening. They will have a physical exam. They will have blood and urine tests and tests of heart function. They may have imaging scans. Researchers will review tissue samples of participant s tumors. In some cases, a new biopsy may be needed.

Participants will receive up to 6 cycles of treatment.

The first cycle is 26 days: Participants will take pomalidomide by mouth for 10 days. After 5 days they will start receiving chemotherapy drugs through a tube attached to a needle placed in a vein (IV). Some participants will receive rituximab on day 5. All participants will receive a second set of IV drugs that will last for 4 days (96 hours). They will receive another IV drug after the previous treatment is complete.

The remaining cycles are each 21 days. Participants will take pomalidomide by mouth for the first 10 days. Other chemotherapy treatments will also be repeated starting on day 1 of each cycle.

Screening tests will be repeated at study visits.

Follow-up visits will continue for 4 years....

Description:

Background:

• Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general population due in part to CD4+ T-cell lymphopenia but also immune dysregulation and exhaustion from chronic viral antigen stimulation.

• The most common NHL subtypes are diffuse large cell lymphoma (DLBCL) and Burkitt lymphoma (BL), that are much more frequently associated with the oncogenic virus Epstein Barr virus (EBV) in PLWH, which portends a poorer prognosis, than in the general population.

• Plasmablastic lymphoma (PBL) is a rare CD20 negative B cell lymphoma associated with EBV almost exclusively seen in PLWH.

• Although these subtypes of lymphoma occur in the general population, their presentation and pathogenesis may be different - meaning there may be different therapeutic targets and strategies to consider in HIV-associated lymphomas necessitating clinical trials targeted to this underserved population of patients.

• Lenalidomide, a 2nd generation immunomodulatory drug, has shown safety and improved survival in combination with chemotherapy in advanced stage DLBCL in one of two randomized trials.

• Pomalidomide, a 3rd generation immunomodulatory agent, has activity in primary CNS lymphoma demonstrating its activity in both NHL and CNS involvement, which is more common in PLWH and NHL. In a number of parameters, it is more potent than lenalidomide.

• Pomalidomide has shown to increase NK and T-cell activation and reverse T-cell senescence in addition to increasing CD4+ T-cell count in PLWH and cancer. It can also enhance expression of

surface immune markers in vitro in cell lines from EBV-induced tumors.

-Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) along with rituximab (DA-EPOCH-R) is an anthracycline-based regimen that has been shown to be safe and effective in PLWH and in the most common subtypes of NHL seen in PLWH, DLBCL and BL.

Objective:

-Determine the safety and maximum tolerated dose (MTD) of the combination of pomalidomide and dose-adjusted EPOCH +/ rituximab (DA-EPOCH-RP) in participants with enrolled subtypes of HIV-associated lymphomas

Eligibility:

• Adult participants >= 18 years with pathology-confirmed HIV-associated B-cell non-Hodgkin lymphoma with high-risk features, excluding primary CNS lymphoma

• Positive HIV1/2 serology

Design:

-This is a phase 1 study of pomalidomide in combination with DA-EPOCH +/- Rituximab (DA-EPOCH-RP) in participants with HIV-associated B-cell non-Hodgkin lymphoma. Only participants with CD20+ HIV-associated B-cell non-Hodgkin lymphoma will receive

Rituximab.

• This is a dose escalation study to evaluate pomalidomide in combination with modified DA-EPOCH-R to determine safety and tolerability. Dosing will begin at dose level 1, 3 mg of pomalidomide and proceed to dose escalation or de-escalation to doses 4 mg or 2 mg depending on dose-limiting toxicities.

• Participants will be prescribed antiretroviral therapy (ART).

• In this phase I study, up to 12 evaluable participants will be accrued in the escalation phase (3-6 participants per level) and up to 6 evaluable participants will be accrued in the expansion phase to be treated at MTD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: June 1, 2032
• Est. primary completion date: June 1, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

• INCLUSION CRITERIA:

• Participants must have histologically or cytologically confirmed B-cell non-Hodgkin lymphoma confirmed by the Laboratory of Pathology, NCI, with one or more of the following features:

• Leptomeningeal/CSF involvement

• High-risk for CNS relapse per CNS-IPI (score 4-6)

• Plasmablastic histology

• Gammaherpesvirus positive tumor

• Presence of Kaposi sarcoma

• Measurable or evaluable lymphoma.

• Positive HIV1/2 serology.

• Participants may not have received prior curative-intent chemotherapy for lymphoma. Participants who have received prior treatment as a bridge to curative-intent therapy will be considered per Protocol Chair discretion if >= 2 weeks since administration. Steroids given for any reason or rituximab given for multicentric Castleman disease may be given any time prior to treatment start.

• Age >=18 years

• ECOG performance status <=4

• Persons of childbearing potential (PCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 14 days prior to and again within 1 day before starting pomalidomide and must either commit to continued abstinence from penetrative vaginal intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before the participant starts taking pomalidomide and for 12 months after the last dose of combined chemotherapy.

• All study participants must agree to be registered into the mandatory POMALYST REMS[Registered]TM program and be willing and able to comply with the requirements of the POMALYST REMS[Registered]TM program.

• Able to take aspirin 81mg orally daily or another substitute thromboprophylaxis.

• Participants must have adequate organ and marrow function as defined below unless abnormalities are attributed to lymphoma or HIV as determined by investigator:

• absolute neutrophil count >=1,000/mcL

• platelets >=75,000/mcL

• total bilirubin <=1.5 X institutional upper limit of normal (participants with history of Gilbert disease are eligible if total bilirubin <= 5 mg/dL with <80% unconjugated bilirubin)

• AST(SGOT)/ALT(SGPT) <=3 X institutional upper limit of normal

• creatinine clearance >=60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal.

• Participants with hepatitis B virus (HBV) infection must be on suppressive antiviral therapy.

• Participants must be willing to take and adhere to antiretroviral therapy (participants are not required to be on any specific regimen of antiretroviral therapy).

• Participants must understand and sign a written informed consent document.

EXCLUSION CRITERIA:

• Participants may not receive investigational agents on other clinical trials.

• Participants requiring any of the agents listed as prohibited thearapies.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide or other agents used in study.

• Parenchymal brain involvement with lymphoma.

• Ejection fraction less than 40% by echocardiography (ECHO)

• CTCAEv5.0 Grade 3-4 neuropathy

• History of malignant tumors other than Kaposi sarcoma or KSHV-associated multicentric Castleman Disease, unless:

• In complete remission for >= 1 year from the time response was first documented; or,

• Completely resected basal cell carcinoma; or,

• In situ squamous cell carcinoma of the cervix or anus; or,

• Prior or concurrent malignancy has a natural history or treatment which does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen per Protocol Chair discretion.

• Known drug-related, inherited, or acquired procoagulant disorder including prothrombin gene mutation 20210, antithrombin III deficiency, protein C deficiency, protein S deficiency and antiphospholipid syndrome but not including heterozygosity for the Factor V Leiden mutation or the presence of a lupus anticoagulant in the absence of other criteria for the antiphospholipid syndrome.

• Symptomatic congestive heart failure

• Unstable angina pectoris, or cardiac arrhythmia.

• Uncontrolled intercurrent illness or participants considered to be of poor medical health due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active uncontrolled infection (excluding lymphoma or HIV) as documented in prior records or suggested by medical history, physical examination or standard clinical assessments such as imaging and laboratory studies.

• Pregnant or breast-feeding persons (if lactating, must agree not to breast feed while taking pomalidomide).

Related Conditions & MeSH terms

• B-Cell Neoplasm
• Burkitt Lymphoma
• Diffuse Large Cell Lymphoma
• Lymphoma
• Lymphoma, AIDS-Related
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Large-Cell, Immunoblastic
• Lymphoma, Non-Hodgkin
• Non-Hodgkin Lymphoma
• Plasmablastic Lymphoma

Intervention

Drug:
• Vincristine
0.4 mg/m2/day administered by CIVI on days 1 to 4
• Prednisone
60 mg/m2/day administered orally on days 1 to 5
• Doxorubicin
10 mg/m2/day administered by CIVI on days 1 to 4
• Etoposide
50 mg/m2/day administered by CIVI on days 1 to 4
• Pomalidomide
An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.
• Cyclophosphamide
750 mg/m2 administered IV on day 5
• Rituximab
375 mg/m2 administered IV on day 1 (only for CD20+ tumors)

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	safety and tolerability	The fraction of patients with toxicity noted at each dose level will be reported by grade and type of toxicity identified. Maximum tolerated dose will also be reported.	6 cycles of treatment, or until confirmed progression, unacceptable toxicity or trial withdrawal
Secondary	progression-free survival	duration of time from the start of the treatment until time of disease relapse from PR, disease progression, or death, whichever occurs first	every 3 weeks for the first 6 cycles, every 3 months for the rest of the first year, then every 6 months for 4 years (5 years total).
Secondary	preliminary estimates of response	Percentage of participants with the best overall response of CR or PR to therapy	every 3 weeks for the first 6 cycles, every 3 months for the rest of the first year, then every 6 months for 4 years (5 years total).

External Links

•   NIH Clinical Center Detailed Web Page